Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences' Finished Goods history runs 9 years deep, the most recent figure standing at $13.6 million for Q1 2025.

• Quarterly Finished Goods rose 81.33% year-over-year to $13.6 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $13.6 million (up 81.33% YoY) and the FY2024 annual result came in at $12.8 million, up 4.07% from the prior year.
• Finished Goods was $13.6 million for Q1 2025 at Neurocrine Biosciences, up from $12.8 million in the prior quarter.
• Across five years, Finished Goods topped out at $17.5 million in Q4 2022 and bottomed at $7.5 million in Q1 2024.
• A 5-year average of $12.7 million and a median of $12.5 million in 2023 frame the typical range for Finished Goods.
• Annual changes were most pronounced in 2023 — Finished Goods fell 29.71% — and 2025, when it soared 81.33%.
• Neurocrine Biosciences' Finished Goods stood at $15.7 million in 2021, then gained by 11.46% to $17.5 million in 2022, then decreased by 29.71% to $12.3 million in 2023, then increased by 4.07% to $12.8 million in 2024, then grew by 6.25% to $13.6 million in 2025.
• Business Quant data shows NBIX's Finished Goods at $13.6 million in Q1 2025, $12.8 million in Q4 2024, and $11.5 million in Q3 2024.